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The HIV-1 long terminal repeat (LTR) responds to a variety of cellular signal transduction pathways. We demonstrate that
the cAMP-dependent protein kinase A (PKA) and protein kinase C (PKC) signaling pathways synergize to increase HIV-1
LTR-mediated transcription and viral replication in a latently infected promonocytic cell line (U1). The LTR-mediated synergy
induced by cholera toxin (Ctx), a potent activator of the cAMP-dependent PKA pathway, and the PKC activator phorbol
12-myristate 13-acetate (PMA) was abrogated by a PKC-b-specific inhibitor (LY333531). In contrast, the LTR-mediated
synergy induced by Ctx and TNFa was not affected by LY333531. The synergy induced by Ctx and TNFa was also abrogated
by mutation of the cAMP-responsive downstream sequence elements (DSE) in the 59 untranslated leader region, whereas the
DSE mutations did not affect the synergy induced by Ctx and PMA. These distinctions indicate that Ctx cooperates differently
with TNFa and PMA to activate the HIV-1 LTR. Ctx and PMA synergistically activated AP-1- and NF-kB-dependent
transcription, even though no cooperative binding of AP-1 or NF-kB was observed in gel shift assays. An extensive mutational
analysis of the HIV-1 LTR that included the NF-kB and AP-1 binding sites revealed no distinct cis-acting element or region
within the HIV-1 LTR that was required for the transcriptional synergy. Ctx and PMA also synergistically interact to activate
the HTLV-1 LTR. These results indicate that the transcriptional synergy elicited by Ctx and PMA targets multiple functional
elements and promoters, requires a cooperative interaction between the PKA and PKC-b pathways, and differs mechanis-
tically from the transcriptional synergy induced by Ctx and TNFa. © 1998 Academic Press
INTRODUCTION
HIV-1 gene expression is activated by multiple signal
transduction pathways (Poli et al., 1995; Tong-Starkesen
et al., 1989; Valerie et al., 1996; Vicenzi and Poli, 1994)
which can function in concert to dramatically increase
transcription from the HIV-1 long terminal repeat (LTR)
(Han et al., 1996; Poli et al., 1994). For example, the
proinflammatory cytokine TNFa cooperates with IL-10 to
produce a synergistic increase in HIV-1 expression in the
latently infected promonocytic U1 cell line (Finnegan et
al., 1996; Weissman et al., 1995; Angel et al., 1995).
Although many signal transduction pathways activate the
HIV-1 LTR, the functional integration of these activation
signals by the LTR to stimulate viral transcription are not
well understood.
Many signal transduction pathways converge to target
the transcription factor NF-kB, which activates HIV-1 ex-
pression by binding to the kB enhancer sites in the LTR
(Chen et al., 1997). NF-kB is a critical mediator of cyto-
kine-induced expression (Emilie et al., 1994; Read et al.,
1997) and is associated with monocyte differentiation
(Griffin et al., 1991). In the cytoplasm, NF-kB is com-
plexed with I-kB, an inhibitor protein that prevents NF-kB
from migrating to the nucleus and binding DNA. In re-
sponse to a variety of stimuli, including phorbol esters,
cytokines, and oxidant stress, I-kB is phosphorylated
and proteolytically degraded, permiting NF-kB to trans-
locate to the nucleus and bind its cognate binding sites
in the HIV-1 enhancer (DiDonato et al., 1997).
A key signaling intermediate in the activation of HIV-1
is protein kinase C (PKC) (Burnette et al., 1993;
Chowdhury et al., 1990; Coates et al., 1997; Dominguez et
al., 1993; Izumi, 1995; Jakobovits et al., 1990; Kim et al.,
1996; Patzold et al., 1993; Qatsha et al., 1993; Tong-
Starkesen et al., 1989). The PKC activator phorbol 13-
myristate 12-acetate (PMA) activates the HIV-1 LTR in U1
cells (Kinter et al., 1990), through the induction of cellular
transcription factors such as NF-kB and AP-1 (Biswas et
al., 1994; Laurence et al., 1990; Roebuck et al., 1996).
AP-1 is composed of heterodimers of Jun and Fos (Angel
et al., 1987; Chiu et al., 1988), and can bind TRE (TPA/
phorbol ester responsive element) sites in the HIV-1
genome (Canonne-Hergaux et al., 1995; el Kharroubi and
Verdin, 1994; Li et al., 1994; Roebuck et al., 1993, 1996;
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Van Lint et al., 1991). We recently identified TRE-like
cAMP-responsive downstream sequence elements
(termed DSE) in the 59 untranslated leader region (UTR)
of the HIV-1 LTR (Roebuck et al., 1993) and showed that
cholera toxin (Ctx), an activator of the cAMP-dependent
protein kinase A (PKA) pathway (Chowdhury et al., 1993),
activates viral transcription through the DSE sites (Rabbi
et al., 1997). The DSE can bind both AP-1 and CREB/ATF
proteins (Rabbi et al., 1997) and mediate synergistic
activation of HIV-1 gene expression induced by the com-
bination of Ctx and TNFa (Rabbi et al., 1997).
Ctx has also been shown to cooperate with PMA in U1
cells (Chowdhury et al., 1993), but the mechanism has
not been examined. In order to understand the functional
interaction between the PKA and PKC pathways, we
sought to determine the functional basis by which Ctx
and PMA activation signals cooperate to activate the
HIV-1 provirus in U1 cells. We demonstrate that Ctx
cooperates with PMA differently than with TNFa in the
induction of HIV-1 gene expression. In contrast to TNFa,
PMA cooperated with Ctx to activate the HIV-1 LTR via
the PKC-b pathway. However, no specific transcriptional
element that mediates the induced synergy, including the
kB enhancer and AP-1-binding DSE, was identified. Our
results indicate that the PKA and PKC pathways syner-
gistically interact through multiple LTR elements to acti-
vate HIV-1 proviral transcription.
RESULTS
Cholera toxin and PMA synergistically activate HIV-1
transcription via PKC-b
As shown in Fig. 1, Ctx cooperated with PMA to pro-
duce a clearly synergistic increase in HIV-1 p24 antigen
production (Fig. 1A) and LTR-mediated gene expression
(Fig. 1B), demonstrating that the two agonists act in
concert to activate HIV-1 proviral transcription in U1
cells. Moreover, the PKC-b-specific inhibitor LY333531
reduced the PMA response and abrogated the synergis-
tic increase in LTR-mediated expression (Fig. 1B), indi-
cating that the PKC-b signaling pathway is critical for the
cooperation between Ctx and PMA. In contrast, the in-
hibitor had no effect on LTR activity induced by the
combination of Ctx and TNFa (data not shown), indicat-
ing that Ctx cooperates differently with PMA and TNFa.
Although Ctx has been reported to increase the intracel-
lular levels of cAMP in U1 cells (Chowdhury et al., 1993),
Fig. 2 shows that exogenous cAMP can also cooperate
with PMA to synergistically increase HIV-1 gene expres-
sion. Taken together, these results demonstrate that the
Ctx activation pathway can synergistically interact with
the PKC-b pathway to activate HIV-1 gene expression.
Cholera toxin and PMA synergistically activate AP-1
and NF-kB
The transcription factors AP-1 and NF-kB are modu-
lated by the PKC and PKA pathways (Angel et al., 1987;
Bomsztyk et al., 1991; Lahdenpohja et al., 1996; Laurence
et al., 1990; Serkkola and Hurme, 1993). To determine
FIG. 1. Effects of cholera toxin and phorbol ester on HIV-1 gene
expression in U1 cells. (A) Cholera toxin cooperates with phorbol ester
to produce a synergistic increase in HIV-1 p24 core antigen production.
U1 cells were treated with phorbol ester (PMA), cholera toxin (Ctx), or
the combination for 72 h. HIV-1 expression was assessed by measur-
ing p24 core antigen in the supernatants by ELISA. The data represent
the mean fold increase over untreated control cells plus the standard
error of three separate experiments. Note the strong synergy between
Ctx and PMA. (B) Cholera toxin and phorbol ester cooperate to increase
HIV-1 LTR activity through the PKC-b pathway. U1 cells were trans-
fected with full-length HIV-1 LTR CAT construct as described under
Materials and Methods and treated with PMA, Ctx, or the combination
for 24 h in the presence (open bars) or absence (solid bars) of the
PKC-b-specific inhibitor LY333531 (20 nM). The data represent the
mean fold increase over untreated control cells plus the standard error
of three separate experiments. Note the marked inhibition of the tran-
scriptional synergy induced by Ctx and PMA.
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whether Ctx and PMA could cooperate to activate NF-kB
and AP-1 in U1 cells, we first assessed AP-1 and NF-kB
binding activity by electrophoretic mobility shift assays
(EMSA). As shown in Fig. 3, Ctx and PMA individually
induced specific DNA binding complexes on the NF-kB
(Fig. 3A) and AP-1 binding sites (Fig. 3B), but the combi-
nation of Ctx and PMA did not further increase DNA
binding activity on these elements. The binding com-
plexes were specific since the binding activity was com-
peted by specific but not by nonspecific oligonucleo-
tides. Suboptimal concentrations of agonists also did not
induce synergy on DNA binding activity (data not shown).
These data indicate that, although Ctx and PMA activate
AP-1 and NF-kB activity, they do not cooperate to induce
synergistic DNA binding.
To determine whether Ctx and PMA could functionally
cooperate to stimulate transcriptional activity through
AP-1 and NF-kB binding sites, LTR CAT constructs, con-
taining four consensus AP-1 or mutant AP-1 binding sites
in place of the viral TAR element downstream of tran-
scription, were transfected into U1 cells (Fig. 4A). We
showed previously that these downstream AP-1 binding
sites could mediate PMA activation signals (Roebuck et
al., 1996). As shown in Fig. 4B, Ctx cooperated with PMA
to produce a synergistic increase in LTR-mediated CAT
activity. In contrast, the construct containing mutant AP-1
sites did not produce even additive effects, indicating
that the AP-1 binding sites mediated the cooperativity
between Ctx and PMA.
To determine whether AP-1 and NF-kB binding sites
can mediate synergy between Ctx and PMA independent
of HIV-1 LTR sequences, a construct containing four
consensus AP-1 binding sites upstream of the rat pro-
lactin TATA element and a construct containing two
NF-kB binding sites upsteam of the cfos TATA element
were transfected into U1 cells (Fig. 5A). We showed
previously that these constructs could mediate PMA ac-
tivation signals through the AP-1 and NF-kB sites
(Kagnoff et al., 1991; Omary et al., 1991; Rabbi et al., 1997;
Roebuck et al., 1997). As shown in Figs. 5B and 5C, Ctx
FIG. 1—Continued
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and PMA cooperated to produce a supra-synergistic
increase in reporter gene activity. In contrast, the paren-
tal plasmids lacking the NF-kB or AP-1 binding sites
were not responsive to either PMA or PMA plus Ctx (data
not shown). Thus, despite their independent effects on
binding activity, Ctx and PMA can functionally cooperate
to activate NF-kB- and AP-1-dependent transcription.
Synergistic activation of the HIV-1 LTR does not
require the kB enhancer or AP-1 binding sites
To determine whether the NF-kB and AP-1 binding sites
within the HIV-1 LTR mediate the transcriptional synergy
induced by Ctx and PMA, the LTR CAT constructs shown in
Fig. 6 were transfected into U1 cells. These LTR constructs
contain deletions of either the NF-kB binding sites of the
upstream enhancer or the downstream cAMP-responsive
AP-1 binding sites in the 59 UTR (DSE). As shown in Fig. 7A,
a deletion of upstream LTR sequences of the negative
regulatory element (NRE) (2120 LTR 1 232 CAT) enhanced
the PMA response, but had no significant effect on the
transcriptional synergy. Nor did further deletion of LTR se-
quences to 276, which removed the NF-kB binding sites
and a Sp1 binding site (276 LTR 1 232 CAT). These data
demonstrate that the kB enhancer element is not essential
for the transcriptional synergy induced by Ctx and PMA.
To assess the contribution of the 59 UTR, we transfected
constructs containing deletion of the 59 UTR from nucleo-
tide positions 139 to 1222, which removes the AP-1 bind-
ing DSE sites. Deletion of the 59 UTR in either the wild-type
(WT LTR DSst CAT) or NRE deleted (2120 LTRDSst CAT)
constructs markedly reduced the Ctx and PMA responses,
but did not affect their ability to mediate a synergistic
transcriptional response (Fig. 7A). Other LTR constructs
with mutation or deletion of the 59 UTR also mediated the
transcriptional synergy (Figs. 7B and 7C). These data dem-
onstrate that although the sequences in the 59 UTR con-
tribute to the agonist responses, they are not required for
the transcriptional synergy induced by the combination of
Ctx and PMA. Collectively, the functional studies clearly
demonstrate that despite the marked effects of the various
LTR mutations on the individual Ctx and PMA responses
none were able to abrogate the combined transcriptional
synergy.
Cholera toxin and PMA synergistically activate HTLV-I
transcription
To determine whether other retroviruses could re-
spond to Ctx and PMA activation signals, we assessed
the ability of the human T-cell leukemia virus type 1
(HTLV-1) LTR to mediate transcriptional synergy. Like
HIV-1, the HTLV-1 LTR contains TRE-like cAMP-respon-
sive elements, but the two retroviruses have been shown
to be activated by PMA through different signaling path-
ways (Mor-Vaknin et al., 1997). The HTLV-I LTR LUC
reporter construct was transfected into U1 cells and
treated with Ctx, PMA, or the combination, and protein
extracts were assessed for luciferase activity. As shown
in Fig. 8, Ctx and PMA each stimulated LTR-mediated
luciferase activity and in combination produced a syner-
gistic increase of nearly 500-fold, indicating that the
HTLV-1 LTR can also functionally integrate Ctx and PMA
activation signals.
DISCUSSION
The HIV-1 LTR responds to a variety of cellular signal
transduction pathways. To study the interaction of the
PKA and PKC pathways in latently infected cells of a
monocyte/macrophage lineage, we have investigated
the mechanism by which Ctx cooperates with PMA or
TNFa to activate HIV-1 expression. Our results indicate
that the transcriptional synergy elicited by Ctx and PMA
targets multiple functional elements and promoters, re-
quires a cooperative interaction between the PKA and
PKC-b pathways, and differs mechanistically from the
transcriptional synergy induced by Ctx and TNFa. Ctx
and PMA synergistically activated transcription from
FIG. 2. cAMP cooperates with phorbol ester to increase HIV-1 LTR
activity. U1 cells were transfected with the full-length HIV-1 LTR CAT
construct and treated with dibutyric cyclic AMP (cAMP), phorbol ester
(PMA), or the combination for 24 h. The data represent the mean fold
increase over untreated control cells plus the standard error of three
separate experiments.
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AP-1 and NF-kB binding sites as well as the HIV-1 and
HTLV-1 LTR.
Perhaps the most unexpected finding of the study was
that Ctx cooperated differently with TNFa and PMA even
though both of these agonists have been reported to
activate PKC. Ctx cooperated with PMA, but not TNFa,
through the PKC-b pathway, since the PKC-b-specific
inhibitor LY333531 blocked the induced synergy elicited
by Ctx and PMA, but not that induced by Ctx and TNFa
(K. A. Roebuck, unpublished data). This is consistent with
the findings of Kim et al., (1996), which demonstrated that
PMA induction of HIV-1 expression was blocked by anti-
PKC-b antibodies, but not by anti-PKC-a or PKC-g anti-
bodies. It is also consistent with reports demonstrating
that NF-kB induction of HIV-1 expression occurs through
PKC-z (Folgueira et al., 1996). Unlike TNFa, which coop-
erates with Ctx through the cAMP-responsive DSE sites
(Rabbi et al., 1997), the cooperation between Ctx and
PMA was not affected by the DSE mutations. Thus, PMA
and TNFa appear to cooperate with the PKA pathway
induced by Ctx through different PKC isoform signaling
pathways.
With regard to the synergy elicited by Ctx and PMA
activation signals, several studies have demonstrated
cross talk between the PKA and PKC signaling pathways
activated by these agonists. For example, phorbol ester
can affect cholera toxin-stimulated cAMP synthesis (Ge-
bicke-Haerter et al., 1994; Krakauer, 1996; Morimoto and
Koshland, 1994; Raufman, 1992) and cAMP can modulate
PKC activity through phosphorylation by PKA (Wooten et
al., 1996). In terms of transcription factor targets, we
showed that at the transcriptional level Ctx and PMA
activation signals display supraadditive effects on re-
porter genes containing PMA responsive elements (i.e.,
binding sites for NF-kB and AP-1), indicating that the
functional cooperativity between Ctx and PMA can be
transmitted by either AP-1 or NF-kB binding. Although
AP-1 and NF-kB contribute to the Ctx and PMA re-
FIG. 3. Cholera toxin and phorbol ester increase transcription factor binding activity. U1 cells were treated with 100 ng/ml cholera toxin (Ctx), 10
ng/ml phorbol ester (PMA), or the combination for 2 h and nuclear protein extracts prepared as described under Materials and Methods. DNA binding
activity was assessed by EMSA using end-labeled NF-kB consensus binding site (A) or AP-1 binding oligonucleotide corresponding to the HIV-1 1160
DSE site (B). Competition using unlabeled specific (S) and nonspecific (NS) oligonucleotides and Ctx plus PMA treated extracts demonstrates the
specificity of the binding complexes. The specific oligonucleotide corresponded to the homologous NF-kB or AP-1 site and the nonspecific was an
oligonucleotide containing the GAS element. The solid triangles indicate competition with 50- and 500-fold molar excess of unlabeled oligonucleotide.
(B) 500 molar excess of unlabeled oligonucleotide was used for competition using Ctx plus PMA treated extracts. Note that the combination of Ctx
and PMA does not increase DNA binding activity.
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sponses (Rabbi et al., 1997) and can cooperate to acti-
vate the HIV-1 LTR (Stein et al., 1993), such functional
cooperation does not appear to be the mechanism me-
diating agonist synergy, since mutation of either the kB
enhancer or AP-1 binding sites in the 59 UTR did not
interfere with transcriptional synergy. Thus, the PKC and
PKA activation signals probably cooperate prior to tran-
scription factor activation involving the functional inter-
action of distinct signaling intermediates. Alternatively,
the synergy could occur subsequent to transcription fac-
tor binding to the LTR involving functional interactions
during the assembly of the transcription preinitiation
complex.
Finally, with regard to pathogenesis, HIV-1 infection
itself can alter cellular signaling pathways (Bernardo et
al., 1994; Ruegg and Strand, 1991), which may contribute
to disease progression (Haraguchi et al., 1995; Hofmann
et al., 1993b; Wyss-Coray et al., 1996). HIV-1 infection has
been associated with sustained elevation of cAMP in
T-cell lines (Nokta and Pollard, 1991, 1992) and normal
FIG. 4. Cholera toxin and phorbol ester act in concert to synergistically increase AP-1-dependent LTR activity. U1 cells were transfected with either
the LTR AP-1 CAT (solid bars) or LTR AP-1m CAT (open bars) constructs (A) and treated with cholera toxin (Ctx), phorbol ester (PMA), or the
combination for 24 h (B). The data represent the mean fold increase over untreated control cells plus the standard error of three separate experiments.
Note that the Ctx and PMA synergy is dependent on functional AP-1 binding sites.
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peripheral lymphocytes (Hofmann et al., 1993a). We re-
cently showed that HIV-1 infection rapidly increases nu-
clear CREB/ATF binding activity to sites in the 59 UTR
(Rabbi et al., 1997). HIV-1 infection can also alter the PKC
pathway (Gupta et al., 1994). In particular, the gp120 viral
surface protein can alter PKC activity (Gibellini et al.,
1994; Ushijima et al., 1993; Ward et al., 1995). The PKA
and PKC pathways have also been implicated in the
CMV enhancement of HIV-1 replication (Hassan et al.,
1993). Because the PKA and PKC pathways can cooper-
ate to activate latent proviral gene expression, virus
infection may stimulate these pathways to produce an
intracellular environment favorable to its own replication.
MATERIALS AND METHODS
Plasmids and LTR CAT constructs
The HIV-1 WT LTR1232 CAT, 2120 LTR1232 CAT, 291
LTR1232 CAT, 291 M6 LTR1232 CAT, 276 LTR1232
CAT, and WT LTR180 CAT reporter plasmids were de-
scribed previously (Rabbi et al., 1997; Roebuck et al.,
1993, 1996). The WT LTR1232 CAT construct contains a
full-length LTR from 2453 to 1232. The 291 M6
LTR1232 CAT is identical to the 291 LTR1232 CAT with
the exception of the point mutations in the DSE located
at nucleotide positions 195 and 1160, which abrogate
their function. The WT LTR DSst CAT, 291 LTR DSst CAT,
FIG. 5. Cholera toxin and phorbol ester cooperate to mediate AP-1- and NF-kB-dependent gene expression. (A) U1 cells were transfected with AP-1-
or NF-kB-dependent reporter gene constructs. AP-1 LUC contains four AP-1 binding sites upstream of the rat prolactin TATA box linked to a firefly
luciferase gene. The NF-kB CAT construct contains two NF-kB binding sites upstream of the cfos TATA box linked to a CAT gene. The U1 cells
transfected with AP-1 LUC (B) and NF-kB CAT (C) were treated with cholera toxin (Ctx), phorbol ester (PMA), or the combination for 24 h. The data
represent the mean fold increase over untreated control cells plus the standard error of three separate experiments.
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and 2120 LTR DSst CAT constructs were derived from
the WT LTR1232 CAT, 291 LTR 1232 CAT, and 2120
LTR1232 CAT plasmids, respectively. They were gener-
ated by digestion with SstI, removal of the 183-bp frag-
ment between 139 and 1222, and recircularization with
T4 ligase. Because the deletion removes part of the TAR
element, these LTR constructs are not transactivated by
Tat (Roebuck et al., 1997). The 2109 LTR180 LUC con-
struct, obtained from Dr. Calame (Columbia Univ. of Phy-
sicians and Surgeons, NY), contains both NF-kB binding
sites and downstream sequences to 180 (Henderson et
al., 1996). The TRE PL LUC construct contains the pro-
lactin TATA box linked to four AP-1 binding sites (TGAGT-
CAG). The TRE PL LUC is an AP-1-dependent reporter
gene since AP-1 but not CREB/ATF transactivate this
construct (Roebuck et al., 1997). The NF-kB CAT con-
struct, obtained from D. Baltimore (MIT, Cambridge MA),
contains two NF-kB binding sites upstream of the cFos
TATA element (Pierce et al., 1988). The HIV-1 LTR AP-1
CAT and HIV-1 LTR AP-1m CAT plasmids, obtained from
K.-T. Jeang (NIH, Bethesda MD), contain four consensus
AP-1 binding sites (TGAGTCAG) or mutant AP-1 binding
sites in place of TAR, respectively (Berkhout et al., 1990).
The HTLV-1 LTR LUC construct was obtained from the
Tumor Biology Laboratory (NIH).
Cell culture, transient transfections, and reporter
gene assays
The human promonocytic U1 cell line was obtained
from the NIH AIDS Research and Reference Reagent
Program (Bethesda, MD) and propagated in RPMI 1640
medium supplemented with 10% fetal calf serum, 2 mM
L-glutatmine, and 1X antibiotic–antimycotic mix (GIBCO-
BRL). The U1 cells were treated with dibutyric cAMP, Ctx
(Sigma Chemical Co., St. Louis, MO), or PMA as indi-
FIG. 7. The transcriptional synergy induced by cholera toxin and phorbol ester does not require the kB enhancer or elements in the 59 UTR. U1 cells
were transfected with the constructs shown in Fig. 6 as described under Materials and Methods. The data represent the mean fold increase over
untreated control cells plus the standard error of at least three separate experiments. (A) Effect of 59 deletions and 59 UTR deletions on agonist
synergy. Transfected cells were treated with 100 ng/ml cholera toxin (Ctx), 10 ng/ml phorbol ester (PMA), or the combination for 24 h. (B) Comparison
of 291 LTR derived constructs. U1 cells were transfected with the 291 LTR 1232 WT CAT (solid bars), 291 M6 LTR 1232 CAT, or 291 LTR DSst CAT
constructs and treated with cholera toxin (Ctx), phorbol ester (PMA), or the combination for 24 h. (C) Comparison of LTR 180 constructs. U1 cells were
transfected with the indicated LTR CAT constructs containing 59 UTR sequences to 180 and treated with 100 ng/ml Ctx, 10 ng/ml PMA, or the
combination for 24 h.
FIG. 6. Structure of HIV-1 LTR reporter gene constructs used in transfection studies. The name of each construct is shown to the left and indicates
the amount of LTR linked to the reporter gene relative to the transcription initiation site. The NF-kB, Sp1, and DSE sites are indicated by solid
rectangles. Mutations in the DSE that create NotI and BssH II restriction sites are indicated by checkered rectangles in the 291 M6 LTR 1232 CAT
construct. The presence or absence of a functional TAR element is indicated by the boxed arrow that marks the transcription start site (11). The
internal deletion of sequence between 139 and 1222 of the WT LTR DSst CAT, 2120 LTR DSst CAT, and 291 LTR DSst CAT constructs was created
by deletion of the SstI restriction fragment as indicated by the solid line.
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cated in the figure legends and assayed 72 h later for
HIV-1 p24 antigen production by ELISA (AIDS Vaccine
Program, Fredrick, MD). The PKC-b-specific inhibitor, ob-
tained from Dr. Kirk Ways (Eli Lilly Co., Indianapolis, IN),
was added to cells 60 min prior to stimulation with
agonist. U1 cells were transfected by the DEAE–dextran
method as previously described (Finnegan et al., 1996).
Chloramphenicol acetyltransferase (CAT) (Enzyme Cata-
logue No. 2.3.1.28) and firefly (Photinus pyralis) luciferase
(Enzyme Catalogue No. 1.13.12.7) assays were performed
as described previously (Roebuck et al., 1993). The mean
fold increase over untreated control cells was calculated
using equivalent amounts of protein cell extract in at
least three independent transfections.
FIG. 7—Continued
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DNA binding studies
EMSA were performed as described (Rabbi et al., 1997).
Briefly, nuclear protein extracts (2–4 mg protein) prepared
from U1 cells by the method of Schreiber et al. (1989) were
incubated with 50,000 CPM (;0.2 ng) of 32P-end-labeled
oligonucleotide probes (NF-kB consensus: 59-AGTTGA-
GGGGACTTTCCCAGGC-39 and AP-1: 59-GACCCTTTTAGT-
CAGTGTGGAA-39 from the HIV-1 1160 site) for 20–30 min
at room temperature in a 20-ml reaction volume containing
12% glycerol, 12 mM Hepes-NaOH (pH 7.9), 60 mM KCl, 5
mM MgCl2, 4 mM Tris–Cl (pH 7.9), 0.6 mM EDTA (pH 7.9),
and 0.6 mM DTT. For specificity of the reaction, 50- to
500-fold molar excess of a nonspecific oligonucleotide (59-
GTGCATTTCCCGTAAATCTTGTCTACA-39) was included in
the binding reaction. Protein–DNA complexes were re-
solved in 5% polyacrylamide gels preelectrophoresed for 30
min at room temperature in 0.25X TBE buffer (22.5 mM
Tris–borate and 0.5 mM EDTA, pH 8.3). Gels were dried and
exposed overnight to radiographic film with an intensifying
screen at 270°C.
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